(Q47214984)

English

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity

scientific article published on 27 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

angiogenesis inhibitor

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Razelle Kurzrock

10

object named as

Razelle Kurzrock

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

8

object named as

Aung Naing

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Charles F. Levenback

6

object named as

Charles Levenback

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

author name string

John Moroney

1

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Siqing Fu

2

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Stacy Moulder

3

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Gerald Falchook

4

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Thorunn Helgason

5

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

David Hong

7

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Jennifer Wheler

9

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

language of work or name

0 references

publication date

27 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

18

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

20

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

5796-5805

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Identifiers

10.1158/1078-0432.CCR-12-1158

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 January 2018

http://europepmc.org/abstract/MED/22927482

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47214984&oldid=2146485337"